Pharmacy Times

JUNE 16, 2025

SHOW MORE This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025. Literature suggests a 3% difference in the rate of FN between CSF agents filgrastim (Neupogen; Amgen)/filgrastim biosimilars and pegfilgrastim (Neulasta; Amgen)/pegfilgrastim biosimilars.

Inpatient 26

Inpatient HIV Treatment and Prevention Agents Pharmacy Technician Chemotherapy 26

Pharmacy Times

JUNE 10, 2025

3 Although meloxicam injection delivers a non-opioid alternative for pain control, it is not recommended as a first-line agent when rapid onset of analgesia is needed due to its delayed onset. June 10, 2025. Accessed June 10, 2025. 2 REFERENCES 1. PR Newswire. Meloxicam: Selective COX-2 inhibition in clinical practice.

Pharmacy Technician 29

Pharmacy Technician HIV Treatment and Prevention Agents Compounding Pharmacies Biosimilars 29

Putting Patients First Blog

NOVEMBER 12, 2024

Recognizing PrEP as a preventive service rather than as indicative of an active medical condition, as HHS proposes, could help address the current risk selection seen in the market. Clear guidance on the treatment of rebates within the ACF will help avoid distortions in pricing and prevent patients from bearing disproportionate costs.

Insurance Coverage and Processing 52

Insurance Coverage and Processing HIV Treatment and Prevention Agents Communication Hospitals 52